Orchestra BioMed surpasses enrollment target in BACKBEAT pivotal trial of AVIM hypertension therapy
Bitget2026/10/01 12:04- Orchestra BioMed surpassed full enrollment in the BACKBEAT pivotal trial of its AVIM Therapy for uncontrolled hypertension in pacemaker patients.
- 330 patients were randomized as of Sept. 30, 2026, exceeding the planned enrollment level intended to support the primary analysis.
- Primary endpoint results have not been presented; data are slated for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027.
- Positive results could support Medtronic marketing application submissions to the FDA and other regulators for the therapy.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Jefferies lowers target price for Antero Resources
Euro-area Inflation: Headline pressures rise – Nordea
Broadcom and Blackstone jointly raise $60 billions to pave the way for AI compute power for companies such as Anthropic
Broadcom is leading a $60 billion debt financing initiative to provide funding for AI companies such as Anthropic to purchase chips and build data centers. Of this amount, $42 billion in senior secured bonds will be syndicated by Broadcom with Wall Street banks, while $18 billion in subordinated debt is being led by Blackstone, whose funds have committed $9 billion. The deal has been in preparation for several weeks but has not yet been officially announced.
Crypto prices
More
